Valuation : Matinas BioPharma Holdings, Inc.

Market Cap 2.73M 2.36M 2.22M 2.02M 3.78M 258M 3.81M 26.29M 10.2M 132M 10.26M 10.04M 434M P/E 2024
-0.1x
P/E 2025 -0.29x
Enterprise Value 87.86K 75.8K 71.4K 65.06K 122K 8.3M 123K 845K 328K 4.24M 330K 323K 13.94M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
76.25%
Yield 2024 *
-
Yield 2025 -
1 day-5.92%
1 week-5.30%
Current month-5.92%
1 month-36.69%
3 months-75.72%
6 months-69.93%
Current year-68.26%
1 week 0.19
Extreme 0.1851
0.2
1 month 0.18
Extreme 0.178
0.32
Current year 0.18
Extreme 0.178
0.91
1 year 0.18
Extreme 0.178
2.14
3 years 0.18
Extreme 0.178
44.5
5 years 0.18
Extreme 0.178
80.5
10 years 0.18
Extreme 0.178
199.5
Manager TitleAgeSince
Chief Executive Officer 52 16/03/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 52 14/03/2025
Director/Board Member 61 05/02/2025
Director/Board Member 55 11/03/2025
Date Insider Type Main position Quantity % Market Cap. Importance
30/04/25 Free

Chief Executive Officer

70,100 1.3780%
30/04/25 Free

Director

11,600 0.2280%
30/04/25 Free

Director

11,600 0.2280%
Change 5-day change 1-year change 3-year change Capi.($)
-5.92%-5.30%-89.84%-97.85% 2.73M
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.51%+0.75%+49.77%+92.50% 65.29B
+4.21%+1.80%-12.85%+459.32% 27.65B
+2.97%+0.40%+38.60%+12.79% 25.77B
+1.83%-7.77%+3.17%-14.74% 26.08B
+1.77%+2.31%+27.63%-16.75% 20.14B
-0.38%-17.67%+214.37%+373.18% 17.03B
+0.77%-5.28%-3.25%+539.79% 15.03B
+2.88%+4.33%+57.42%+157.39% 14.5B
Average +1.07%-3.30%+32.43%+160.02% 28.04B
Weighted average by Cap. +1.76%-2.35%+41.61%+148.42%

Financials

2024 2025
Net sales - -
Net income -24.25M -20.92M -19.71M -17.96M -33.56M -2.29B -33.82M -233M -90.55M -1.17B -91.06M -89.07M -3.85B -10.34M -8.92M -8.41M -7.66M -14.32M -977M -14.43M -99.53M -38.63M -500M -38.85M -38M -1.64B
Net Debt -4.39M -3.79M -3.57M -3.25M -6.08M -415M -6.12M -42.24M -16.39M -212M -16.48M -16.12M -696M -2.64M -2.28M -2.15M -1.96M -3.66M -250M -3.69M -25.45M -9.88M -128M -9.93M -9.72M -420M
Logo Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Employees
2
Date Price Change Volume
02/09/26 $0.1860 -5.92% 379,052
01/09/26 $0.1977 0.00% 342,652
31/08/26 $0.1977 -1.15% 458,982
28/08/26 $0.2000 0.00% 406,400
27/08/26 $0.2000 +1.83% 816,854

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MTNB Stock